“a nonsignificant trend”

However, among critically ill COVID-19 positive patients treated by the ACS service, there was a nonsignificant trend toward lower mortality (13.9 vs. 27.4%, P = .12).

Patients with detectable KRAS ctDNA but preserved PNI (≥ 45) also demonstrated a nonsignificant trend toward worse survival (HR 2.22, 95% CI 0.82–5.99, p = 0.12).

1.15; Wilcoxon test, p = 0.047), whereas a nonsignificant trend toward higher ratios was observed in rural versus urban infants (1.71 vs. 1.29; p = 0.12). 3.4.

3.4 Association of Paced QRS Duration, V6RWPT and Development of PICM There was a nonsignificant trend toward patients developing PICM having a wider paced QRS duration than those without PICM (144 ± 20 vs. 135 ± 19, p = 0.12) and the incidence of PICM tended to be higher in patients with a paced QRS duration > 150 ms compared with the patients with paced QRS duration ≤ 150 ms (5 of 35, 14.3% vs. 8 of 138, 5.8%, p = 0.14).

In contrast, detectable MRD in CEBPA non‐bzip AML patients showed a nonsignificant trend towards increased CIR and inferior OS ( p = 0.12 and p = 0.24; Figure 1E,F ).

Direct comparison of cutoff values revealed that while CRP ≥2.0 mg/L—commonly used in Western populations—showed only a nonsignificant trend for MACE prediction in this analysis (RR: 1.20; 95% CI: 0.95-1.52; P = 0.12), a threshold of ≥1.0 mg/L was a significantly stronger predictor (RR: 1.50; 95% CI: 1.14-1.97; P = 0.004).

( Table 1 ) Renal Impairment : A nonsignificant trend favored Mg (6.2% vs. 13.8%, p=0.12), aligning with Mg’s vasodilatory and anti-ischemic renal protective effects.

While OS showed a nonsignificant trend towards shorter survival in stage III/IV cases ( p = 0.12), PFS was significantly worse in the stage III/IV group ( p < 0.001) ( Figure 5 ).

The T3c stage showed a nonsignificant trend towards a higher risk of metastasis compared with T3a (OR 2.9, 95% CI 0.8–10.9, P = 0.12).

These reveal a nonsignificant trend for a reduction with treatment in the likelihood of suspension for Black and Hispanic students, b = 0.04, P = 0.12.

Fisher's exact test indicated a nonsignificant trend for BRCA1 expression and a history of ovarian cancer ( P =0.12).

Although HCT-ALB independently predicts mortality, it showed a nonsignificant trend toward superior discrimination compared to HCT alone ( P = 0.12), it was significantly inferior to ALB ( P < 0.001).

Furthermore, streptomycin- resistant isolates were not more frequent in older age groups, although there was a nonsignificant trend (p = 0.12; chi-squaretrend).

The transferrin saturation showed a nonsignificant trend of being slightly lower in the intervention arm compared with the standard-of-care arm (median difference, −4.0%; 95% CI, −11.0 to 2.0; P = 0.12).

A nonsignificant trend toward more severe ED could be seen among patients with DLBCL ( P = .12).

All-cause mortality With semaglutide treatment, a nonsignificant trend toward reduced all-cause mortality was observed (RR: 0.79; 95% CI: 0.59–1.07; p = 0.12; I 2 = 61%) (Supplemental Digital Content Fig. 2 , available at: http://links.lww.com/MS9/A760 ).

Subgroups and secondary endpoints There was no evidence of effect modification by BCLC stage (interaction p = 0.28) or HBV status (interaction p = 0.34), and only a nonsignificant trend toward stronger associations in non-curative versus curative therapy settings (interaction p = 0.12) (Table 3 ).

There was a nonsignificant trend toward higher incidence of HCC among CHB patients who were HDV positive vs HDV negative (1.28 vs 0.41 per 100,000 person-years, P = .12) ( Table 5 , Figure ).

High levels of STING in tumor cells were of borderline significance ( P = .066), and analysis of total STING had a nonsignificant trend for improved DFS ( P = .12).

29 , 30 Notably, this appeared to be driven by fewer cases of stroke (HR: 0.61, 95% CI: 0.38–0.99, p = 0.04), with a nonsignificant trend for reduced risk of nonfatal MI (HR: 0.74, 95% CI: 0.51–1.08, p = 0.12).

This difference was statistically significant in stage II ( P = .046), while a nonsignificant trend favoring EGFRmu was observed in stage IA ( P = .12; Supplemental Figure 4 ).

A nonsignificant trend toward increased OS was observed in the wild-type group (median OS was 14.5 months vs 12.5 months, HR =0.85, 95% CI: 0.70–1.04; P =0.12), and a 35% improvement in the response rate against 10% was observed with the addition of panitumumab.

Schizophrenia and the incidence of liver cancer stratified by gender The pooled results of five cohorts [ 20 , 22 – 25 ], which all excluded patients with cancer events before the diagnosis of schizophrenia, showed that schizophrenia was associated with a significantly higher incidence of liver cancer in male patients (SIR: 0.71, 95% CI: 0.56–0.90, p = 0.005; I 2 = 79%; Figure 3 ), but a nonsignificant trend of a higher incidence of liver cancer in female patients (SIR: 0.83, 95% CI: 0.65–1.05, p = 0.12; I 2 = 63%; Figure 3 ).

A nonsignificant trend toward increased OS was observed; median OS was 14.5 months vs. 12.5 months, respectively (HR = 0.85, p = 0.12); RR improved to 35% vs. 10% with the addition of panitumumab.

A nonsignificant trend toward better OS for later-enrolled patients was demonstrated when comparing all 4 quartiles ( P = .12; supplemental Figure 14 A).